Vanda Pharmaceuticals' Tradipitant Under FDA Review Extension

The US FDA has extended its re-review of Vanda Pharmaceuticals' tradipitant for motion sickness by a few days. Tradipitant is a medication under investigation for the treatment of motion sickness. The FDA initially placed a partial clinical hold on long-term studies of tradipitant in September 2022. The agency was supposed to complete its review by November 26, but due to the extension, the review will now be completed by December 2.